Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice

FASEB Journal

Volumn 29, Issue 6, 2015, Pages 2504-2513

  Akagi, Daisuke ^a   Chen, Mian ^a   Toy, Robert ^a   Chatterjee, Anuran ^a   Conte, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fatty acid; Inflammation; Neointimal hyperplasia; Vascular remodeling

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MARESIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; OMEGA 3 FATTY ACID; PLATELET DERIVED GROWTH FACTOR; POLYUNSATURATED FATTY ACID; PRORESOLVING LIPID MEDIATOR; RESOLVIN D2; SUPEROXIDE; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; 7,14-DIHYDROXYDOCOSA-4,8,10,12,16,19-HEXAENOIC ACID; CYTOKINE; KI 67 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTERY WALL; ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL REACTIVITY; CAROTID ARTERY LIGATION; CELL MIGRATION; CELL POLARITY; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HOMEOSTASIS; IC50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SYSTEMIC THERAPY; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CAROTID ARTERY; CELL CULTURE; CELL MOTION; CYTOLOGY; DRUG EFFECTS; GENETICS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INTIMA; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; NEOINTIMA; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE;

MUS;

ANIMALS; CAROTID ARTERIES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DOCOSAHEXAENOIC ACIDS; GENE EXPRESSION; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; KI-67 ANTIGEN; MALE; MICE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; NEUTROPHIL INFILTRATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPEROXIDES; TUMOR NECROSIS FACTOR-ALPHA; TUNICA INTIMA; VASCULAR REMODELING;

EID: 84933528986     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-265363     Document Type: Article

References (46)

1. Fowkes, F. G., Rudan, D., Rudan, I., Aboyans, V., Denenberg, J. O., McDermott, M. M., Norman, P. E., Sampson, U. K., Williams, L. J., Mensah, G. A., and Criqui, M. H. (2013) Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 382, 1329-1340
2. Saw, J., Bhatt, D. L., Moliterno, D. J., Brener, S. J., Steinhubl, S. R., Lincoff, A. M., Tcheng, J. E., Harrington, R. A., Simoons, M., Hu, T., Sheikh, M. A., Kereiakes, D. J., and Topol, E. J. (2006) The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J. Am. Coll. Cardiol. 48, 1567-1572
3. Jones, D. W., Schanzer, A., Zhao, Y., MacKenzie, T. A., Nolan, B. W., Conte, M. S., and Goodney, P. P.; Vascular Study Group of New England. (2013) Growing impact of restenosis on the surgical treatment of peripheral arterial disease. J Am Heart Assoc 2, e000345
4. Ross, R. (1999) Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340, 115-126
5. Fredman, G., and Serhan, C. N. (2011) Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem. J. 437, 185-197
6. Serhan, C. N. (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92-101
7. Serhan, C. N., Yang, R., Martinod, K., Kasuga, K., Pillai, P. S., Porter, T. F., Oh, S. F., and Spite, M. (2009) Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 206, 15-23
8. Gong, J., Wu, Z. Y., Qi, H., Chen, L., Li, H. B., Li, B., Yao, C. Y., Wang, Y. X., Wu, J., Yuan, S. Y., Yao, S. L., and Shang, Y. (2014) Maresin 1 mitigates lipopolysaccharide-induced acute lung injury in mice. Br. J. Pharmacol. 171, 3539-3550
9. Marcon, R., Bento, A. F., Dutra, R. C., Bicca, M. A., Leite, D. F., and Calixto, J. B. (2013) Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis. J. Immunol. 191, 4288-4298
10. Serhan, C. N., Dalli, J., Karamnov, S., Choi, A., Park, C. K., Xu, Z. Z., Ji, R. R., Zhu, M., and Petasis, N. A. (2012) Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J. 26, 1755-1765
11. Merched, A. J., Ko, K., Gotlinger, K. H., Serhan, C. N., and Chan, L. (2008) Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 22, 3595-3606
12. Ho, K. J., Spite, M., Owens, C. D., Lancero, H., Kroemer, A. H., Pande, R., Creager, M. A., Serhan, C. N., and Conte, M. S. (2010) Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am. J. Pathol. 177, 2116-2123
13. Miyahara, T., Runge, S., Chatterjee, A., Chen, M., Mottola, G., Fitzgerald, J. M., Serhan, C. N., and Conte, M. S. (2013) D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J. 27, 2220-2232
14. Geisterfer, A. A., Peach, M. J., and Owens, G. K. (1988) Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ. Res. 62, 749-756
15. Ho, K. J., Owens, C. D., Longo, T., Sui, X. X., Ifantides, C., and Conte, M. S. (2008) C-reactive protein and vein graft disease: evidence for a direct effect on smooth muscle cell phenotype via modulation of PDGF receptor-beta. Am. J. Physiol. Heart Circ. Physiol. 295, H1132-H1140
16. Li, P., Zhu, N., Yi, B., Wang, N., Chen, M., You, X., Zhao, X., Solomides, C. C., Qin, Y., and Sun, J. (2013) MicroRNA-663 regulates human vascular smooth muscle cell phenotypic switch and vascular neointimal formation. Circ. Res. 113, 1117-1127
17. Kumar, A., and Lindner, V. (1997) Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler. Thromb. Vasc. Biol. 17, 2238-2244
18. Serhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., and Gronert, K. (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204
19. Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., and Moussignac, R. L. (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037
20. Spite, M., Norling, L. V., Summers, L., Yang, R., Cooper, D., Petasis, N. A., Flower, R. J., Perretti, M., and Serhan, C. N. (2009) Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461, 1287-1291
21. Bento, A. F., Claudino, R. F., Dutra, R. C., Marcon, R., and Calixto, J. B. (2011) Omega-3 fatty acid-derived mediators 17 (R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J. Immunol. 187, 1957-1969
22. Park, C. K., Xu, Z. Z., Liu, T., Lü, N., Serhan, C. N., and Ji, R. R. (2011) Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1. J. Neurosci. 31, 18433-18438
23. Klein, C. P., Sperotto, N. D., Maciel, I. S., Leite, C. E., Souza, A. H., and Campos, M. M. (2014) Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice. Neuropharmacology 86, 57-66
24. Bohr, S., Patel, S. J., Sarin, D., Irimia, D., Yarmush, M. L., and Berthiaume, F. (2013) Resolvin D2 prevents secondary thrombosis and necrosis in a mouse burn wound model. Wound Repair Regen. 21, 35-43
25. Kurihara, T., Jones, C. N., Yu, Y. M., Fischman, A. J., Watada, S., Tompkins, R. G., Fagan, S. P., and Irimia, D. (2013) Resolvin D2 restores neutrophil directionality and improves survival after burns. FASEB J. 27, 2270-2281
26. Steffens, J. P., Herrera, B. S., Coimbra, L. S., Stephens, D. N., Rossa, C., Jr., Spolidorio, L. C., Kantarci, A., and Van Dyke, T. E. (2014) Testosterone regulates bone response to inflammation. Horm. Metab. Res. 46, 193-200
27. McCauley, L. K., Dalli, J., Koh, A. J., Chiang, N., and Serhan, C. N. (2014) Cutting edge: Parathyroid hormone facilitates macrophage efferocytosis in bone marrow via proresolving mediators resolvin D1 and resolvin D2. J. Immunol. 193, 26-29
28. Katakura, M., Hashimoto, M., Inoue, T., Al Mamun, A., Tanabe, Y., Iwamoto, R., Arita, M., Tsuchikura, S., and Shido, O. (2014) Omega-3 fatty acids protect renal functions by increasing docosahexaenoic acid-derived metabolite levels in SHR. Cg-Lepr (cp)/NDmcr rats, a metabolic syndrome model. Molecules 19, 3247-3263
29. Godin, D., Ivan, E., Johnson, C., Magid, R., and Galis, Z. S. (2000) Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation 102, 2861-2866
30. Khatri, J. J., Johnson, C., Magid, R., Lessner, S. M., Laude, K. M., Dikalov, S. I., Harrison, D. G., Sung, H. J., Rong, Y., and Galis, Z. S. (2004) Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 109, 520-525
31. Nam, D., Ni, C. W., Rezvan, A., Suo, J., Budzyn, K., Llanos, A., Harrison, D., Giddens, D., and Jo, H. (2009) Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 297, H1535-H1543
32. Kumar, A., Hoover, J. L., Simmons, C. A., Lindner, V., and Shebuski, R. J. (1997) Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. Circulation 96, 4333-4342
33. Holt, A. W., and Tulis, D. A. (2013) Experimental Rat and Mouse Carotid Artery Surgery: Injury & Remodeling Studies. ISRN Minim Invasive Surg 2013, 167407
34. Petri, M. H., Laguna-Fernandez, A., Tseng, C. N., Hedin, U., Perretti, M., and Bäck, M. (2015) Aspirin-triggered 15-epi-lipoxin A. signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation. Int. J. Cardiol. 179, 370-372
35. Korshunov, V. A., Nikonenko, T. A., Tkachuk, V. A., Brooks, A., and Berk, B. C. (2006) Interleukin-18 and macrophage migration inhibitory factor are associated with increased carotid intimamedia thickening. Arterioscler. Thromb. Vasc. Biol. 26, 295-300
36. Carr, M. W., Roth, S. J., Luther, E., Rose, S. S., and Springer, T. A. (1994) Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. USA 91, 3652-3656
37. Xu, L. L., Warren, M. K., Rose, W. L., Gong, W., and Wang, J. M. (1996) Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J. Leukoc. Biol. 60, 365-371
38. Xia, M., and Sui, Z. (2009) Recent developments in CCR2 antagonists. Expert Opin Ther Pat 19, 295-303
39. Fujiu, K., Wang, J., and Nagai, R. (2014) Cardioprotective function of cardiac macrophages. Cardiovasc. Res. 102, 232-239
40. Wynn, T. A., Chawla, A., and Pollard, J. W. (2013) Macrophage biology in development, homeostasis and disease. Nature 496, 445-455
41. Danenberg, H. D., Fishbein, I., Gao, J., Mönkkönen, J., Reich, R., Gati, I., Moerman, E., and Golomb, G. (2002) Macrophage depletion by clodronate-containing liposomes reduces neointimal formationafter balloon injury in ratsandrabbits. Circulation 106, 599-605
42. Stoneman, V., Braganza, D., Figg, N., Mercer, J., Lang, R., Goddard, M., and Bennett, M. (2007) Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ. Res. 100, 884-893
43. Titos, E., Rius, B., González-Périz, A., López-Vicario, C., Morán-Salvador, E., Martínez-Clemente, M., Arroyo, V., and Clària, J. (2011) Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J. Immunol. 187, 5408-5418
44. Hsiao, H. M., Sapinoro, R. E., Thatcher, T. H., Croasdell, A., Levy, E. P., Fulton, R. A., Olsen, K. C., Pollock, S. J., Serhan, C. N., Phipps, R. P., and Sime, P. J. (2013) A novel antiinflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLoS ONE 8, e58258
45. Dalli, J., Zhu, M., Vlasenko, N. A., Deng, B., Haeggström, J. Z., Petasis, N. A., and Serhan, C. N. (2013) The novel 13S, 14S-epoxymaresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J. 27, 2573-2583
46. Nosova, E. V., Chong, K. C., Alley, H. F., Harris, W. S., Boscardin, W. J., Conte, M. S., Owens, C. D., and Grenon, S. M. (2014) Clinical correlates of red blood cell omega-3 fatty acid content in male veterans with peripheral arterial disease. J. Vasc. Surg. 60, 1325-1331